Luoxin Pharmaceuticals Group Stock Co., Ltd. (SHE:002793)
China · Delayed Price · Currency is CNY 5.31
+0.11 (2.12%)
Aug 20, 2026, 3:04 PM CST
SHE:002793 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 5,775 | 5,095 | 4,055 | 5,829 | 8,342 | 15,181 | |
Market Cap Growth | -8.26% | 25.65% | -30.44% | -30.12% | -45.05% | -0.22% |
Enterprise Value | 6,271 | 6,055 | 5,305 | 6,876 | 11,056 | 16,161 |
Last Close Price | 5.31 | 4.80 | 3.82 | 5.36 | 7.67 | 10.34 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | - | - | 37.38 |
PS Ratio | 2.46 | 2.24 | 1.53 | 2.47 | 2.33 | 2.34 |
PB Ratio | 4.80 | 4.12 | 2.78 | 2.27 | 2.52 | 3.21 |
P/TBV Ratio | 7.71 | 6.66 | 4.54 | 2.93 | 3.00 | 3.76 |
P/FCF Ratio | 18.55 | 23.07 | - | 25.97 | - | - |
P/OCF Ratio | 16.72 | 20.14 | - | 12.49 | - | 125.85 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.68 | 2.66 | 2.00 | 2.91 | 3.08 | 2.50 |
EV/EBITDA Ratio | 54.97 | 163.70 | - | - | - | 22.90 |
EV/EBIT Ratio | - | - | - | - | - | 31.10 |
EV/FCF Ratio | 20.14 | 27.41 | - | 30.63 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 1.04 | 0.89 | 1.12 | 0.59 | 1.10 | 0.60 |
Debt / EBITDA Ratio | 23.44 | 24.12 | - | - | - | 3.97 |
Debt / FCF Ratio | 5.91 | 4.97 | - | 6.77 | - | - |
Net Debt / Equity Ratio | 0.36 | 0.44 | 0.81 | 0.32 | 0.66 | 0.17 |
Net Debt / EBITDA Ratio | 9.60 | 14.70 | -4.16 | -2.86 | -1.56 | 1.17 |
Net Debt / FCF Ratio | 2.03 | 2.46 | -4.33 | 3.68 | -1.91 | -4.37 |
Asset Turnover | 0.62 | 0.56 | 0.56 | 0.36 | 0.41 | 0.75 |
Inventory Turnover | 2.85 | 3.02 | 3.51 | 2.35 | 3.86 | 4.77 |
Quick Ratio | 0.56 | 0.51 | 0.48 | 0.79 | 0.85 | 1.34 |
Current Ratio | 0.76 | 0.84 | 0.70 | 1.08 | 1.08 | 1.59 |
Return on Equity (ROE) | -19.47% | -21.11% | -52.20% | -26.16% | -31.26% | 9.28% |
Return on Assets (ROA) | -2.49% | -2.46% | -6.31% | -4.53% | -11.35% | 3.77% |
Return on Invested Capital (ROIC) | -9.03% | -7.17% | -15.79% | -10.81% | -28.99% | 8.96% |
Return on Capital Employed (ROCE) | -12.10% | -11.10% | -26.50% | -15.00% | -42.70% | 9.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -4.44% | -5.66% | -23.81% | -11.34% | -14.68% | 2.67% |
FCF Yield | 5.39% | 4.33% | -6.74% | 3.85% | -13.59% | -1.24% |
Dividend Yield | - | - | - | - | - | 0.29% |
Payout Ratio | - | - | - | - | - | 32.59% |
Buyback Yield / Dilution | -3.44% | 0.39% | 1.65% | 23.91% | 1.79% | 0.51% |
Total Shareholder Return | -3.44% | 0.39% | 1.65% | 23.91% | 1.79% | 0.80% |